Literature DB >> 16912162

Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Zongxiang Zhou1, Andrea Flesken-Nikitin, David C Corney, Wei Wang, David W Goodrich, Pradip Roy-Burman, Alexander Yu Nikitin.   

Abstract

Pathways mediated by p53 and Rb are frequently altered in aggressive human cancers, including prostate carcinoma. To test directly the roles of p53 and Rb in prostate carcinogenesis, we have conditionally inactivated these genes in the prostate epithelium of the mouse. Inactivation of either p53 or Rb leads to prostatic intraepithelial neoplasia developing from the luminal epithelium by 600 days of age. In contrast, inactivation of both genes results in rapidly developing (median survival, 226 days) carcinomas showing both luminal epithelial and neuroendocrine differentiation. The resulting neoplasms are highly metastatic, resistant to androgen depletion from the early stage of development, and marked with multiple gene expression signatures commonly found in human prostate carcinomas. Interestingly, gains at 4qC3 and 4qD2.2 and loss at 14qA2-qD2 have been consistently found by comparative genomic hybridization. These loci contain such human cancer-related genes as Nfib, L-myc, and Nkx3.1, respectively. Our studies show a critical role for p53 and Rb deficiency in prostate carcinogenesis and identify likely secondary genetic alterations. The new genetically defined model should be particularly valuable for providing new molecular insights into the pathogenesis of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912162     DOI: 10.1158/0008-5472.CAN-06-0486

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  143 in total

1.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 2.  Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Authors:  Frederick Bauzon; Liang Zhu
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

3.  Advanced neuroendocrine prostate tumors regress to stemness.

Authors:  Leigh Ellis; Massimo Loda
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-17       Impact factor: 11.205

4.  E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo.

Authors:  Huifang Sun; Yanqing Wang; Meenalakshmi Chinnam; Xiaojing Zhang; Simon W Hayward; Barbara A Foster; Alexander Y Nikitin; Marcia Wills; David W Goodrich
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

5.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas.

Authors:  Monica Gostissa; Julia M Bianco; Daniel J Malkin; Jeffery L Kutok; Scott J Rodig; Herbert C Morse; Craig H Bassing; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

7.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

8.  Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.

Authors:  Jeffrey J Tosoian; Michael A Gorin; Steven P Rowe; Darian Andreas; Zsolt Szabo; Kenneth J Pienta; Martin G Pomper; Tamara L Lotan; Ashley E Ross
Journal:  Clin Genitourin Cancer       Date:  2016-09-19       Impact factor: 2.872

Review 9.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

10.  Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Authors:  Michael D Nyquist; Alexandra Corella; Ilsa Coleman; Navonil De Sarkar; Arja Kaipainen; Gavin Ha; Roman Gulati; Lisa Ang; Payel Chatterjee; Jared Lucas; Colin Pritchard; Gail Risbridger; John Isaacs; Bruce Montgomery; Colm Morrissey; Eva Corey; Peter S Nelson
Journal:  Cell Rep       Date:  2020-05-26       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.